Comprehensive analysis identifies CLEC1B as a potential prognostic biomarker in hepatocellular carcinoma
© 2023. The Author(s)..
BACKGROUND: C-type lectin domain family 1 member B (CLEC1B, encoding the CLEC-2 protein), a member of the C-type lectin superfamily, is a type II transmembrane receptor involved in platelet activation, angiogenesis, and immune and inflammatory responses. However, data regarding its function and clinical prognostic value in hepatocellular carcinoma (HCC) remain scarce.
METHODS: The expression of CLEC1B was explored using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. RT-qPCR, western blot, and immunohistochemistry assays were employed to validate the downregulation of CLEC1B. Univariate Cox regression and survival analyses were used to evaluate the prognostic value of CLEC1B. Gene Set Enrichment Analysis (GSEA) was conducted to investigate the potential association between cancer hallmarks and CLEC1B expression. The TISIDB database was applied to search for the correlation between immune cell infiltration levels and CLEC1B expression. The association between CLEC1B and immunomodulators was conducted by Spearman correlation analysis based on the Sangerbox platform. Annexin V-FITC/PI apoptosis kit was used for the detection of cell apoptosis.
RESULTS: The expression of CLEC1B was low in various tumors and exhibited a promising clinical prognostic value for HCC patients. The expression level of CLEC1B was tightly associated with the infiltration of various immune cells in the HCC tumor microenvironment (TME) and positively correlated with a bulk of immunomodulators. In addition, CLEC1B and its related genes or interacting proteins are implicated in multiple immune-related processes and signaling pathways. Moreover, overexpression of CLEC1B significantly influenced the treatment effects of sorafenib on HCC cells.
CONCLUSIONS: Our results reveal that CLEC1B could serve as a potential prognostic biomarker and may be a novel immunoregulator for HCC. However, its function in immune regulation should be further explored.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
Cancer cell international - 23(2023), 1 vom: 12. Juni, Seite 113 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jing, Qiangan [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarker |
---|
Anmerkungen: |
Date Revised 16.06.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1186/s12935-023-02939-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM35810565X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM35810565X | ||
003 | DE-627 | ||
005 | 20231226074033.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12935-023-02939-1 |2 doi | |
028 | 5 | 2 | |a pubmed24n1193.xml |
035 | |a (DE-627)NLM35810565X | ||
035 | |a (NLM)37308868 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Jing, Qiangan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comprehensive analysis identifies CLEC1B as a potential prognostic biomarker in hepatocellular carcinoma |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 16.06.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a BACKGROUND: C-type lectin domain family 1 member B (CLEC1B, encoding the CLEC-2 protein), a member of the C-type lectin superfamily, is a type II transmembrane receptor involved in platelet activation, angiogenesis, and immune and inflammatory responses. However, data regarding its function and clinical prognostic value in hepatocellular carcinoma (HCC) remain scarce | ||
520 | |a METHODS: The expression of CLEC1B was explored using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. RT-qPCR, western blot, and immunohistochemistry assays were employed to validate the downregulation of CLEC1B. Univariate Cox regression and survival analyses were used to evaluate the prognostic value of CLEC1B. Gene Set Enrichment Analysis (GSEA) was conducted to investigate the potential association between cancer hallmarks and CLEC1B expression. The TISIDB database was applied to search for the correlation between immune cell infiltration levels and CLEC1B expression. The association between CLEC1B and immunomodulators was conducted by Spearman correlation analysis based on the Sangerbox platform. Annexin V-FITC/PI apoptosis kit was used for the detection of cell apoptosis | ||
520 | |a RESULTS: The expression of CLEC1B was low in various tumors and exhibited a promising clinical prognostic value for HCC patients. The expression level of CLEC1B was tightly associated with the infiltration of various immune cells in the HCC tumor microenvironment (TME) and positively correlated with a bulk of immunomodulators. In addition, CLEC1B and its related genes or interacting proteins are implicated in multiple immune-related processes and signaling pathways. Moreover, overexpression of CLEC1B significantly influenced the treatment effects of sorafenib on HCC cells | ||
520 | |a CONCLUSIONS: Our results reveal that CLEC1B could serve as a potential prognostic biomarker and may be a novel immunoregulator for HCC. However, its function in immune regulation should be further explored | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Biomarker | |
650 | 4 | |a CLEC1B | |
650 | 4 | |a Hepatocellular carcinoma | |
650 | 4 | |a Immunoregulator | |
650 | 4 | |a Sorafenib | |
650 | 4 | |a Tumor microenvironment | |
700 | 1 | |a Yuan, Chen |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Chaoting |e verfasserin |4 aut | |
700 | 1 | |a Jin, Weidong |e verfasserin |4 aut | |
700 | 1 | |a Wang, Aiwei |e verfasserin |4 aut | |
700 | 1 | |a Wu, Yanfang |e verfasserin |4 aut | |
700 | 1 | |a Shang, Wenzhong |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Guibing |e verfasserin |4 aut | |
700 | 1 | |a Ke, Xia |e verfasserin |4 aut | |
700 | 1 | |a Du, Jing |e verfasserin |4 aut | |
700 | 1 | |a Li, Yanchun |e verfasserin |4 aut | |
700 | 1 | |a Shao, Fangchun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer cell international |d 2001 |g 23(2023), 1 vom: 12. Juni, Seite 113 |w (DE-627)NLM118608711 |x 1475-2867 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:12 |g month:06 |g pages:113 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12935-023-02939-1 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2023 |e 1 |b 12 |c 06 |h 113 |